Clinical trials: Lipoprotein (a)
Blood Pressure, Coagulation Delay
Onion, Cardiovascular Risk Markers and Gene Expression
AIMS: The aims are to investigate whether: Increased intake of onion (powder) affects plasma lipid profile, blood pressure, indices of insulin sensitivity and blood coagulation.
- Trial name
- M197 (NCT02449590)
- Testing
- Onion powder
- Where
- 2 sites in Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Professor Lars Ove Dragsted
Dyslipidemia, Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients
This study will assess the safety, tolerability, and effect of TAP311 on blood lipids in healthy subjects and in patients who have dyslipidemia.
- Trial name
- NCT01487460
- Testing
- TAP311
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Elevated Low-Density Lipoprotein Cholesterol
Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol
This is a Phase 1, multi-center, randomized, double-blinded, placebo-controlled single and multiple dose escalation study with SC doses of SNK-396 in participants with elevated LDL-C.
- Trial name
- NCT05896969
- Testing
- SNK-396 - SAD cohort, SNK-396 - MAD Cohort
- Where
- 3 sites in Australia
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Syneos Health
Elevated Lipoprotein(a)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)
The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS APO(a)-LRx (ISIS 681257) given to healthy volunteer subjects.
- Trial name
- NCT02414594
- Testing
- IONIS-APO(a)-LRx, Sterile Normal Saline (0.9% NaCl)
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hyperlipoproteinemia (a)
A Study of SRSD216 in Patients With Elevated Lipoprotein (a)
This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD216 and to identify a dose range for further studies in subjects with elevated Lp(a) level with or…
- Trial name
- NCT07172646
- Testing
- SRSD216 injection
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Sirius Therapeutics Co., Ltd.
Hyperlipidemias
Effects of Oral Glucose and Teduglutide on Plasma Lipoproteins
Some of the fat (triglyceride) from the food humans eat gets stored in the bowel. This triglyceride can then be released into the blood when another meal is consumed or in response to hormones.
- Trial name
- TED+GLC plasma (NCT03860688)
- Testing
- TED + glucose
- Where
- Canada
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Healthy Volunteers
Effects of a Dietary Supplement on Lipoprotein Lipids and Inflammatory Markers
The goal of this study is to assess the effects of a dietary supplement on fasting lipoprotein lipids and a marker of inflammation in men and women with levels of low-density lipoprotein cholesterol above desirable levels.
- Trial name
- NCT03118583
- Testing
- 300 mg/day of dietary supplement containing carrageenan
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Midwest Center for Metabolic and Cardiovascular Research
To Reduce the LDL-C Level in Hypercholesteremia Adult Patients, Combination for Subgroup High LDL-c Patients With Other Comorbidities
Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects
Objectives: The primary and secondary objectives of the study are presented below. Exploratory objectives are presented in the body of the protocol.
- Trial name
- NCT05905068
- Testing
- RN0191 INJECTION
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Ikaria Bioscience Pty Ltd
Healthy Volunteers
A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol
This is a phase 1 study in otherwise healthy participants with high LDL cholesterol. Following multiple doses of LY3015014, the safety and tolerability of the drug, how the body handles the drug, and the drug's effect on the body…
- Trial name
- NCT01618916
- Testing
- LY3015014
- Where
- 2 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Dyslipidemia
Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)
This study will evaluate whether chronic dosing with Niaspan™ increases reverse cholesterol transport, high-density lipoprotein cholesterol (HDL-C) levels, and fecal excretion of cholesterol.
- Trial name
- NCT01071291
- Testing
- Niaspan
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Participants
A Study of LY2484595 on Pharmacokinetics in Healthy Participants
This is a 2-part study. Part 1 is to determine the safety and tolerability in healthy participants of increasing daily doses of LY2484595 for 14 days to achieve a blood level of LY2484595 much higher than what is needed for…
- Trial name
- NCT01448824
- Testing
- LY2484595, Ketoconazole
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Lipoprotein Disorder, Arterial Stiffness
The Effect of Lipoprotein (a) on Arterial Stiffness, Endothelial Function and Myocardial Deformation
1. Introduction Lipoprotein(a), or Lp(a), is a type of lipoprotein that is structurally similar to LDL (low-density lipoprotein) but carries an additional protein called apolipoprotein (a). 2.
- Conditions
- Lipoprotein Disorder, Arterial Stiffness, Endothelial Dysfunction
- Trial name
- Lpa_endo (NCT07324902)
- Where
- 2 sites in Greece
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Athens
Parkinson Disease
Lipoprotein Metabolism and Bacterial Lipopolysaccharide in Parkinson's Disease
Patients with Parkinson's disease (PD) present an impaired intestinal permeability with consequent lipopolysaccharide (LPS) translocation in the systemic circulation.
- Trial name
- LiMBaLiP (NCT03937284)
- Testing
- Patients not treated
- Where
- Italy
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Milan
Coronary Artery Disease (CAD), Computed Tomography Angiography
AI-assisted CT for Risk Stratification in Coronary Artery Disease (ACTION)
The goal of this observational study is to learn if AI-assisted cardiac CT imaging can improve cardiovascular risk stratification and prediction of future coronary events in an adult population undergoing clinically indicated…
- Conditions
- Coronary Artery Disease (CAD), Computed Tomography Angiography, Biomarkers, AI (Artificial Intelligence)
- Trial name
- ACTION (NCT07577609)
- Where
- Ireland
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- University of Galway
Fatty Acids, Omega-3, Fish Oils
Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals
Background: Fish oils contain omega-3 fatty acids that play important roles in the body. Researchers are studying a new type of fish oil that contains very-long-chain omega-3 fatty acids (VLCPUFAs).
- Trial name
- NCT07882160
- Testing
- VLCPUFA-rich fish oil, DHA-rich fish oil
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Insight Into the Prevalence of Elevated Lp(a) Among Greek Medical Students
Medical Students' Evaluation of Dyslipidemia and LIPoprotein(a) Study
This cross-sectional study aims to determine the prevalence of elevated Lp(a) levels among volunteer medical students at the Faculty of Medicine, University Hospital of Ioannina, Greece.
- Trial name
- MEDLIP (NCT06482476)
- Testing
- Measurement of Lp(a) levels
- Where
- Greece
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- University of Ioannina
Cardiovascular Prevention
A Pilot Study to Investigate Platelet Reactivity in Patients With Elevated Lipoprotein(a) and Its Response to Antiplatelet Therapy
The Lp(a)-PLAT Study is designed to close a critical evidence gap in cardiovascular prevention for the roughly 20% of the population who carry genetically determined elevations in lipoprotein(a) - a recognised pro-thrombotic and…
- Trial name
- Lp(a)-PLAT (NCT07720934)
- Testing
- Aspirin, Clopidogrel
- Where
- Switzerland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- François MACH
Acute Chest Syndrome
ST Elevation in Acute Chest Pain; Could Measurement of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) be Helpful to the Clinician?
A blood test (2-3 cc peripheral venous blood) drawn /used from already available required lab tests to distinguish between pericarditis accompanied with electrocardiogram (ECG) signs mimicking infarction.
- Trial name
- NCT01041339
- Where
- Israel
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alexhander Izhaki
Atherosclerosis, Cardiovascular Diseases
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
The INTENSITY-LOW study aims to answer if there are any limits to LDL reduction in relation to benefitting vascular health from a mechanistic viewpoint, and therefore potentially limitations to primary prevention in healthy…
- Trial name
- NCT03273972
- Testing
- Written Informed Consent, Inclusion/Exclusion check, Full Clinical Chemistry and Haematology Bloods
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Cardiovascular Disease
Clinico-biological Collection of Subjects With Hyper Lipoprotein a in Reunion Island
Cardiovascular disease (CVD) is the second leading cause of death in France and the leading cause of death on Reunion Island. Some modifiable risk factors for cardiovascular diseases are well identified and can be easily…
- Trial name
- COLLIPAR (NCT04310917)
- Testing
- blood lipoprotein (a) test
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de la Réunion